Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Uniwersytet Wroclawski currently maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is situated within 1 distinct art unit and involves 1 distinct examiner. Such a profile reflects a singular focus in the university's current patent prosecution efforts. This concentration within 1 distinct art unit suggests that the university is pursuing a specific line of research that falls under a narrow technical classification at the USPTO.
The busiest examiner for the portfolio is BANERJEE, KOYELI, who is handling 1 busiest examiner pending office action. This single action constitutes the total of 1 pending office action for the entity. With only 1 distinct examiner involved in the current art unit, the prosecution process is highly centralized. This provides a clear and single point of contact for the university's legal representatives, allowing them to tailor their prosecution strategy specifically to the expectations of BANERJEE, KOYELI.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BANERJEE, KOYELI | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564350 | HUMAN FIBROBLAST GROWTH FACTOR 1 (FGF-1) MUTEINS, THEIR DIMERS AND USES | BANERJEE, KOYELI | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564350 | HUMAN FIBROBLAST GROWTH FACTOR 1 (FGF-1) MUTEINS, THEIR DIMERS AND USES | BANERJEE, KOYELI | 1658 | §101§103 | Non-Final OA | — | Pending | Nov 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial